In Brief: Bristol-Myers Squibb
Bristol-Myers Squibb: Maxipime (cefepime) will be reviewed for treatment of febrile episodes in neutropenic patients March 5 by the Anti-Infective Drugs Advisory Committee at a meeting held at the Ramada Inn in Bethesda, Md. The open public hearing begins at 8:30. In the afternoon of March 5 and all of March 6 and 7, committee will discuss document to industry on evaluability criteria for review of anti-microbials at the Division of Anti-Infective Drug Products. Copies of the draft document can be obtained two weeks before the meeting by calling (301) 827-4573. On March 6 and 7, the meeting will be held at the Bethesda Holiday Inn...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth